Amplitude Surgical – Consolidated annual revenue of €110.8 million, up +5.7% at constant exchange rates

  • Business growth of +3.8% at constant exchange rates in the fourth quarter of the 2024-25 financial year and of +5.7% for the full year
  • Strong momentum in France: revenue up +4.8%
  • Solid international business: revenue up +8.2% at constant exchange rates

VALENCE, France–(BUSINESS WIRE)–Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME), the French leader in surgical technologies for lower limb orthopedics, announces its consolidated revenue for the 2024-25 fiscal year.

Olivier Jallabert, CEO of Amplitude Surgical, said: “The Group’s revenue for the 2024-25 fiscal year shows an increase of +5.7% at constant exchange rates compared to the previous fiscal year. Amplitude Surgical has thus recorded another year of growth, both in France, with a 4.8% increase in revenue, and internationally, with an 8.2% increase in activity at constant exchange rates.”

Consolidated revenue for the 2024-25 financial year

Revenue 2024-25June 30, 2025June 30, 2024Change at
current rates
Change at
constant rates
In K€ – IFRS standards
Knee and hip activities110,833106,0194.5%5.7%
Total110,833106,0194.5%5.7%
Revenue Q4 2024-25June 30, 2025June 30, 2024Change at
current rates
Change at
constant rates
In K€ – IFRS standards
Knee and hip activities27,02026,4062.3%3.8%
Total27,02026,4062.3%3.8%

During the 2024-25 financial year, Amplitude Surgical’s revenue amounted to €110.8 million, up 4.5% at current exchange rates and 5.7% at constant exchange rates. Revenue for the 2024-25 financial year was therefore slightly below the outlook published in March 2025, with fourth-quarter growth more moderate than the trend observed for the first nine months of the financial year and unfavorable exchange rate effects, particularly in Australia.

During the 2024-25 financial year, business in France grew by +4.8%, while international distributors posted growth of +2.9% and the Group’s international subsidiaries recorded an increase of +4.1% at current rates and +10.0% at constant rates.

Amplitude Surgical’s direct business (French market and international subsidiaries), which accounts for nearly 93% of the Group’s total sales, grew by 6.0% at constant exchange rates.

France accounts for approximately 73% of the Group’s business.

For international subsidiaries, business grew at constant rates in Belgium, Australia, Brazil, and South Africa, while Switzerland and Germany reported a decline in commercial activity.

EBITDA margin 2024-25

In its press release issued on March 26, 2025, the Company updated its outlook and anticipated an EBITDA margin of approximately 26.5% for the fiscal year ending June 30, 2025. Based on unaudited financial statements as of the date of this press release, the Company anticipates an EBITDA margin of approximately 27%.

Next press release:

2024-25 annual results: Wednesday, October 22, 2025, after market close.

About Amplitude Surgical

Founded in 1997 in Valence, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main pathologies affecting the hip and knee. Amplitude Surgical develops, in close collaboration with surgeons, a number of high value-added innovations to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is expanding internationally through its subsidiaries and a network of exclusive agents and distributors in more than 30 countries. As of June 30, 2025, Amplitude Surgical employed 429 people and generated revenue of nearly €111 million.

Contacts

Amplitude Surgical
Chief Financial Officer
Dimitri Borchtch
finances@amplitude-surgical.com
+33 (0)4 75 41 87 41

NewCap
Investor Relations
Thomas Grojean
amplitude@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
+33 (0)1 44 71 94 98

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use